In this trial, the patients with HF, NYHA class II, III, or IV, low LVEF 40% or less, and elevated levels of proBNP (≥600 pg/mL), received either dapagliflozin (at a dose of 10 mg once daily) or placebo, in addition to the recommended therapy [33]. The gene discussed is NPPB; the disease is hydrops fetalis.